Table 2.
Individual patients with loss of future drug options by end of trial
| Drugs received during trial | Reverse transcriptase mutations | Protease mutations | Lost drug options | |
|---|---|---|---|---|
| OT | ||||
| 1* | ABC, 3TC, ATV | Val118Ile, Val179Asp, Met184Val | Ile84Val | 3TC, FTC, ATV, SQV, FPV, TPV |
| 2 | TDF, FTC, RPV, DRV | Leu100Ile, Lys103Asn, Met184Val | Ala71Val | 3TC, FTC, NVP, EFV, ETV, RPV |
| 3 | TDF, FTC, ETV, NVP, EFV, DRV | Lys65Arg, Glu138Ala, Tyr181Cys, Met184Val/Ile, His221Tyr, Met230Leu | .. | 3TC, FTC, ABC, TDF, NVP, EFV, ETV, RPV |
| 4* | TDF, FTC, DRV | Val106Ala | .. | NVP,‡ EFV‡ |
| PI-mono | ||||
| 5* | ATV | .. | Lys20Thr, Ile50Leu/Ile, Ala71Thr | ATV |
| 6* | DRV | .. | Leu90Met | SQV† |
| 7* | DRV | .. | Ala71Thr, Leu90Met | SQV† |
| 8* | DRV | Lys103Asn | .. | NVP,‡ EFV‡ |
| 9* | DRV | Lys103Asn | .. | NVP,‡ EFV‡ |
| 10* | DRV | Met41Leu, Thr215Asp | .. | ZDV‡ |
OT=ongoing triple therapy. ABC=abacavir. 3TC=lamivudine. ATV=atazanavir. FTC=emtricitabine. SQV=saquinavir. FPV=fosamprenavir. TPV=tipranavir. TDF=tenofovir. RPV=rilpivirine. NVP=nevirapine. EFV= efavirenz. ETV=etravirine. DRV=darunavir. PI-mono=protease inhibitor monotherapy. ZDV=zidovudine.
*
Met primary outcome at 3 years.
†
Possibly archived resistance.
‡
Probably archived resistance (excluded in sensitivity analysis).